Saving changes...

Done

Error

VCS 2020: Keynote, Dr. Mitchell Steiner

VCS 2020: Keynote, Dr. Mitchell Steiner

VCS 2020: Keynote, Dr. Mitchell Steiner

Mitchell Steiner
Mitchell Steiner
on behalf of Missouri Veterinary Medical Association

$FREE $ FREE $ FREE

$ FREE $ FREE $ FREE
$ 25.00 $ 25.00 $ 25.00
Normal Price: FREE $25.00

Review:

Launch date: 22 Nov 2020
Expiry Date:

Last updated: 03 Jan 2021

Reference: 196405

Maximum Attendees:

Places Left: 0

This course is no longer available

Exam is embedded in the course
No preview available
No Exam Available

Latest User Comments

Dianna Saam (6 Dec 2020)
Very Interesting new potential chemo agent.

I would like to...

Course Availability

This course is only available to trainees days after purchase. It would need to be repurchased by the trainee if not completed in the allotted time period. This course is no longer available. You will need to repurchase if you wish to take the course again.

You have null days left.

Description

Antitubulins, like taxanes, are the most widely used and effective agents in human oncology. Unfortunately, antitubulins have major limitations in canine oncology care: intravenous route of administration, high rates of severe hypersensitivity reactions to the cremophor EL solvent, and dose limiting toxicities of severe febrile neutropenia and sepsis. VERU-111 is an oral antitubulin that targets both alpha and beta tubulin subunits of microtubules and could have an important role against canine malignancies. Based on safety studies in dogs, VERU-111 has high oral bioavailability without the hypersensitivity, neurotoxicity and neutropenia dose limiting toxicities typical of taxanes. Preclinical in vitro cell line studies show that VERU-111 has activity against many of the common canine tumors including mast cell tumor, hemangiosarcoma, osteosarcoma, and lymphoid malignancies. A Phase 1 study is currently being planned in dogs with a variety of metastatic cancers. Oral antitubulin VERU-111 could be an important new addition to the armamentarium against canine cancers: ability for home administration and dose changes with efficacy against a broad ranges of cancer types and a better safety profile.
Exam offered and MVMA CE certificate issued following presentation.

Objectives

. The role of microtubules and microtubule targeting agents. Microtubule targeting agents (tubulin inhibitors) are not all the same as they bind to different regions of microtubules with resulting different antitumor efficacy and safety profiles.
The limitations of current taxanes in canine oncology
Understanding the mechanism of VERU-111, a selective oral tubulin inhibitor, that results in both significant antitumor activity against several types of common canine cancers and a more favorable side effect profile in dogs.
Mitchell Steiner

Author Information Play Video Bio

Mitchell Steiner
on behalf of Missouri Veterinary Medical Association

Mitchell Steiner, M.D., F.A.C.S. has served as Chairman of the Board of Directors, President and Chief Executive Officer of the Veru,Inc. (NASDAQ:VERU) October 2016. Dr. Steiner was the co-founder of Aspen Park and served as Aspen Park’s Chief Executive Officer, President and Vice Chairman of the Board from July 2014 to October 2016. From 2014 to 2016, Dr. Steiner was a consultant and then the President, Urology and member of senior management of OPKO Health, Inc. (NASDAQ:OPK) and had responsibilities for the launch, marketing, sales and reimbursement of 4Kscore prostate cancer test to urologists and primary care physicians. Dr. Steiner was also the co-founder of GTx, Inc., a men’s health and oncology public company, where he served as Chief Executive Officer and Vice Chairman of Board of Directors from 1997 to 2014. Dr. Steiner is a Board Certified Urologist and a Fellow of the American College of Surgeons and has held numerous academic appointments, including Assistant Professor of Urology, Cell Biology, and Pathology at Vanderbilt School of Medicine from 1993 to 1995 and Chairman and Professor of Urology, Director of Urologic Oncology and Research and the Chair of Excellence in Urologic Oncology at the University of Tennessee from 1995 to 2004. Dr. Steiner holds a B.A. in Molecular Biology and Chemistry from Vanderbilt University and an M.D. from the University of Tennessee. He performed his surgical and urologic training at The Johns Hopkins Hospital and postdoctoral research fellow in cell biology at Vanderbilt School of Medicine. He has authored over 250 publications and abstracts. He has been named in over 250 patents.

Current Accreditations

This course has been certified by or provided by the following Certified Organization/s:

  • Missouri Veterinary Medical Association
  • 0.25 Hours -
    Exam Attempts: 3
    -
    Exam Pass Rate: 60
  • Veterinary Cancer Society (VSC)
  • 0.25 Units

Faculty and Disclosures

Additional Contributors

Conflicts Declared

Conflicts of Interest declaration by Author:

null

User Reviews (1)

Go Back
Dianna Saam (6 Dec 2020)
Very Interesting new potential chemo agent.

Loading...


Saving changes...

Done

Error